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Insulin increases microvascular perfusion and substrate exchange surface area in muscle, which is pivotal for hormone action 
and substrate exchange, by activating insulin signaling cascade in the endothelial cells to produce nitric oxide. This action of in-
sulin is closely coupled with its metabolic action and type 2 diabetes is associated with both metabolic and microvascular insulin 
resistance. Muscle microvascular perfusion/volume can be assessed by 1-methylxanthine metabolism, contrast-enhanced ultra-
sound and positron emission tomography. In addition to insulin, several factors have been shown to recruit muscle microvascu-
lature, including exercise or muscle contraction, mixed meals, glucagon-like peptide 1 and angiotensin II type 1 receptor (AT1R) 
blocker. On the other hand, factors that cause metabolic insulin resistance, such as inflammatory cytokines, free fatty acids, and 
selective activation of the AT1R, are capable of causing microvascular insulin resistance. Therapies targeting microvascular insu-
lin resistance may help prevent or control diabetes and decrease the associated cardiovascular morbidity and mortality. 
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INTRODUCTION
Patients with type 2 diabetes are at high risk of getting both 
macrovascular and microvascular complications. Though the 
exact underlying mechanisms remain to be elucidated, insulin 
resistance and endothelial dysfunction have been implicated 
to play a major role in their pathogenesis. Insulin, in addition 
to stimulating muscle glucose disposal, also plays important 
role in the regulation of vascular tone and tissue perfusion. We 
and others have shown that insulin plays important vasodila-
tory action on the pre-capillary arterioles in muscle. This leads 
to increased microvascular perfusion and capillary exchange 
surface area in muscle and this effect closely couples with in-
sulin’s metabolic action [1-3]. As it is in the microvasculature 
that the exchanges of nutrients, oxygen, and hormones between 
the plasma compartment and muscle interstitium take place, 
insulin resistance in the microvasculature could play important 
role in the pathogenesis of diabetes and its complications. Here 
we review the regulation of muscle microcirculation in health 
and diabetes. 
STRUCTURE AND FUNCTION OF MUSCLE 
MICROVASCULATURE
Microcirculation encompasses all vessels <150 µm in diame-
ter, including arterioles, capillaries, and venules. Its major func-
tion is to regulate muscle perfusion to ensure adequate delivery 
of nutrients, oxygen and hormones and to provide endothelial 
exchange surface area between the plasma compartment and 
muscle interstitium. Microvascular perfusion is determined by 
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pre-capillary terminal arterioles. Their openings increase mi-
crovascular perfusion and expand endothelial exchange sur-
face area (microvascular recruitment) and their closures lead 
to the opposite (microvascular decruitment) [2]. In the resting 
state only ~30% of the capillaries are being perfused [4]. 
  Muscle microvascular perfusion and endothelial exchange 
surface area play a pivotal role in the regulation of substrate 
metabolism and tissue function. The rate of substrate extrac-
tion ([V]-[A])=([I]-[A])×(1-e
-PS/Q), where V is the venous 
plasma concentration, I is the interstitial concentration, A is 
the arterial plasma concentration, P is surface permeability, S 
is surface area, and Q is the plasma flow rate. Thus, a relatively 
small increase (decrease) in the microvascular surface area 
could markedly increase (decrease) substrate extraction, espe-
cially in skeletal muscle where the resting blood flow is low (3 
to 5 mL/min/100 g).
MEASUREMENT OF MUSCLE 
MICROVASCULAR PERFUSION
Insulin causes vasodilation and increases total muscle blood 
flow [5,6]. However, whether the increase in the bulk muscle 
blood flow contributes to insulin’s metabolic effect in muscle 
was a subject of controversy. As microvasculature provides the 
necessary endothelial surface area for substrate exchange in 
muscle which is pivotal to muscle glucose extraction, several 
techniques have been developed to estimate microvascular 
perfusion in muscle. 
Metabolism of 1-methylxanthine
This technique is based on the metabolism (i.e., the extraction 
across a muscle bed) of 1-methylxanthine (a metabolite of caf-
feine) which is an exogenous substrate for xanthine oxidase. 
This enzyme is highly concentrated in the capillary endothelial 
cells [3,7] and efficiently converts 1-methylxanthine to 1-meth-
yluric acid. Thus the changes in 1-methylxanthine metabolism 
can be used to estimate microvascular blood flow or volume.
Contrast-enhanced ultrasound (CEU) imaging
CEU imaging is a noninvasive technology adapted from the 
myocardial contrast echocardiography technique developed 
by Wei et al. [8-10]. It uses microbubbles (composed of lipid 
shell and gas) as the contrast agent to trace the microvascular 
bed. The microbubbles are smaller than and have a rheology 
similar to the red blood cells. Thus, they can track the move-
ment of red blood cells within the muscle microvasculature. 
To measure skeletal muscle microvascular perfusion, intermit-
tent imaging of the muscle of interest is performed using ultra-
harmonic imaging, with the ultrasound pulses gated to an in-
ternal timer to allow progressively prolonged pulsing intervals 
to allow more replenishment of the microbubbles in the mi-
crocirculation. After a background subtraction to exclude the 
signals generated from large, rapidly filling vessels, the pulsing 
interval (time) versus video-intensity curve is generated and 
fitted to an exponential function: y=A(1-e
-βt), where y is the 
video intensity at a pulsing interval t, A is the plateau video in-
tensity representing microvascular blood volume (MBV), and 
β is the rate constant reflecting the rate of rise of video intensity 
(i.e., microvascular flow velocity, MFV). Microvascular blood 
flow (MBF) is the product of MBV and MFV (i.e., MBF= 
MBV×MFV). CEU is unique in that it provides information 
on three important indices of microvascular flow: MBV which 
reflects the volume of the microvascular bed, MFV which cor-
responds to the rate of red blood cells flow through this micro-
vascular bed, and total microvascular blood flow (MBF). This 
technique has been successfully used in both laboratory ani-
mals and humans in combination with insulin clamp to pro-
vide dual assessment of insulin actions on both microvascula-
ture and muscle glucose disposal [11-16].
Positron-emission tomography (PET) imaging
PET can be used to noninvasively measure blood flow in mus-
cle [17,18]. It uses radiowater ([
15O]H2O) as tracer and mea-
sures blood flow in tissues where there is an exchange of water 
molecules. It has the capacity to provide three-dimensional 
insight into capillary level blood flow in muscle [17]. Other 
than its high cost, the very low tissue uptake of the tracer in-
creases the errors due to the contribution of arterial blood vol-
ume, statistical noise and delay of the arterial input function 
[17]. Nonetheless, as PET can be used to simultaneously de-
termine glucose uptake in muscle in vivo by using 18F-deoxy-
glucose, this modality is valuable in determining the relations 
between muscle blood flow and glucose use. As radiowater is 
freely diffusible which makes it difficult to separate signals 
generated between larger arteries and capillaries, a change of 
the tracer from radiowater to labeled carbon monoxide (C
15O) 
might provide better assessment of microvascular blood flow 
as 
15O labeled carbon monoxide binds rapidly to the heme 
moiety of hemoglobin. 85
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REGULATION OF MUSCLE 
MICROVASCULAR PERFUSION IN HEALTH
Many physiological factors regulate muscle microvascular per-
fusion in vivo, including insulin, exercise, mixed meals, gluca-
gon-like peptide 1 (GLP-1), and angiotensin II type 1 receptor 
(AT1R) blocker. 
  Under normal physiology, insulin upon binding to and ac-
tivation of its receptors on endothelial cell membrane actively 
regulates muscle microvascular perfusion. We and others have 
repeatedly demonstrated a vasodilatory effect of physiological 
concentrations of insulin in the muscle microcirculation in both 
humans and laboratory animals [15,19,20]. Insulin exerts its 
vaso-regulatory actions mainly through two signaling path-
ways. It activates the phosphatidylinositol 3-kinase (PI-3 ki-
nase)/protein kinase B (PKB or Akt) pathway which leads to 
the phosphorylation and activation of the endothelial nitric 
oxide (NO) synthase (eNOS) and NO production [21]. NO is 
a potent vasodilator and causes vasodilation of the peripheral 
resistance arteries and the pre-capillary terminal arterioles, 
leading to increased total blood flow [22] and muscle micro-
vascular perfusion [11,12,15,19,23]. The effect on microvascu-
lar perfusion, or recruitment, occurs rapidly (within 5 to 10 
minutes) [12], and is NO-dependent as inhibition of NO pro-
duction prevents insulin-mediated microvascular recruitment 
[11,12]. On the other hand, activation of the insulin receptors 
also phosphorylates and activates the mitogen-activated pro-
tein kinase (MAPK) pathway which results in the production 
of a potent vasoconstrictor endothelin-1 [24,25]. Thus, insulin 
fine-tunes pre-capillary arteriole tone and muscle perfusion 
via balancing its signals through these two signaling pathways.
  Increased muscle microvascular perfusion not only facili-
tates nutrient exchanges between the plasma compartment 
and muscle interstitium, it also increases muscle delivery of 
insulin. For insulin to exert its metabolic actions it has to be 
first delivered to tissue interstitium. Insulin has been shown to 
regulate its own delivery to muscle insterstitium by dilating 
resistance vessels to increase total blood flow, relaxing pre-cap-
illary arterioles to recruit microvasculature and increase ex-
change surface area (microvascular recruitment), and trans-
endothelial transport of insulin from the plasma compartment 
to interstitium [2]. Insulin-mediated microvascular recruitment 
clearly precedes insulin-stimulated glucose uptake in skeletal 
muscle [12] and blockade of insulin’s microvascular action with 
NOS inhibitor decreases insulin-stimulated glucose disposal 
by ~40% [11,12]. This is thus far the strongest evidence linking 
insulin’s microvascular action to its metabolic action in muscle.
  Muscle contraction is probably the most potent inducer of 
muscle microvascular recruitment. Even light exercise, such as 
gentle hand grip (at 25% of maximal strength) [26], or electric 
stimulation at low frequency that does not increase conduit 
artery blood flow (0.1-Hz contraction) [27,28], significantly 
increases muscle microvascular volume. This low frequency 
muscle contraction also significantly increases muscle uptake 
of insulin, suggesting that the microvascular response to mus-
cle contraction may in part explain enhanced insulin action in 
exercising muscle. Though the underlying signalling pathways 
remain to be studied, NO does not appear to be involved in 
this process as co-infusion of L-NAME, an NOS inhibitor, does 
not appear to blunt muscle contraction-induced microvascu-
lar recruitment [28].
  AT1R blockers have been widely used clinically to treat pa-
tients with hypertension and numerous clinical trials have 
confirmed that they are able to decrease cardiovascular mor-
bidity and mortality and new onset of diabetes in patients with 
various cardiovascular conditions. AT1R blockade leads to un-
opposed action of endogenous angiotensin II on the G-protein-
coupled type 2 receptors (AT2R) (through Giα), resulting in 
increased phosphotyrosine phosphatase activity, inhibition of 
the p44/42 MAPK, and vasodilation via the bradykinin-NO-
cGMP signaling cascade. AT2R antagonist PD123319, brady-
kinin-B2 receptor antagonist icatibant, and NOS inhibition all 
independently blocks AT2R-mediated vasodilatory action [29]. 
Strong in vivo evidence has confirmed the vasodilatory role of 
AT2R in both resistance microvessels as well as in large capaci-
tance vessels including rat uterine artery, mesenteric arterial 
segments, coronary arterioles, and thoracic aorta [29,30]. We 
have recently shown that AT1R blockade with losartan potently 
recruits muscle microvasculature and increases muscle use of 
glucose while specific antagonism of the AT2R with PD123319 
decreases basal microvascular blood volume by ~80% which is 
associated with significantly decreased muscle glucose extrac-
tion and decreased muscle insulin delivery and action [14,31]. 
Thus, selective AT1R blockade may improve insulin sensitivity 
via muscle microvascular recruitment in addition to its inhibi-
tory effect on AT1R-mediated oxidative stress. 
  Mixed meal is another potent muscle microvascular recruit-
ment inducer [15,26,32]. It appears that its effect is stronger 
than insulin alone as raising plasma insulin concentrations to 
levels that are similar to those achieved with mixed meal in-86
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gestion by systemic insulin infusion recruits less microvascu-
lature than mixed meals [15]. This is not surprising as mixed 
meals induce more neural and hormonal changes in vivo in 
addition to inducing insulin secretion. One of the major chang-
es is the secretion of GLP-1 which causes glucose-dependent 
insulin secretion. However, ample evidence has confirmed that 
GLP-1 has many extra-pancreatic effects including a vasodila-
tory action on the vasculature. It has also been shown to stim-
ulate glucose uptake in both cardiac muscle and skeletal mus-
cle independent of insulin. We have recently shown that GLP-
1 potently recruits muscle microvasculature in rats which is 
associated with increased muscle insulin delivery and action. 
These effects are NO-dependent as inhibition of NO produc-
tion completely abolishes GLP-1-induced microvascular re-
cruitment and insulin delivery in muscle [33].
MICROVASCULAR INSULIN RESISTANCE IN 
DIABETES AND OBESITY
Insulin resistance is present in skeletal muscle microcircula-
tion in patients with or animal models of obesity and/or dia-
betes. Basal muscle microvascular volume is decreased in obese 
Zucker rats (an animal model of metabolic syndrome) and 
Zucker diabetic fatty rats (an animal model of type 2 diabetes), 
which is associated with impaired insulin-mediated glucose 
disposal and microvascular recruitment [34,35]. In humans, 
moderate insulin resistance as seen in people with simple obe-
sity blunts insulin- or mixed meal-induced muscle microvas-
cular recruitment [20,32]. It appears that insulin resistance 
only selectively occurs in the PI3-kinase/Akt/eNOS pathway 
and insulin signaling through the MAPK pathway remains in-
tact or even enhanced [21,36,37], leading to decreased NO 
availability and same or enhanced endothelin-1 production, 
tilting the vasomotion balance between endothelin-1 and NO 
production and resulting in vasoconstriction [25,38]. This may 
contribute to the pathogenesis of hypertension and organ dys-
function in patients with diabetes and insulin resistance.
  Though the mechanisms underlying muscle microvascular 
insulin resistance remain to be elucidated, ample evidence has 
confirmed the critical roles of inflammatory cytokines, free 
fatty acids (FFAs) and the activation of vascular renin-angio-
tensin system (RAS) in its pathogenesis. Each of them has been 
shown to blunt insulin-mediated microvascular recruitment 
in muscle. This is not surprising as each of them causes oxida-
tive stress, inflammation, and insulin resistance. However, un-
derlying pathways vary.
  Diabetes and obesity are associated with a chronic elevation 
of inflammatory cytokines in tissue and in plasma. Among 
them tumor necrosis factor-α (TNF-α) has been extensively 
studied and plays critical role in the pathogenesis of insulin re-
sistance in skeletal muscle, adipose tissue, liver and vasculature. 
It also causes microvascular insulin resistance, as evidenced by 
its inhibitory effect on insulin-induced microvascular recruit-
ment and glucose disposal in rats [39], possibly via p-38 MAPK-
mediated insulin resistance through the PI3-kinase pathway 
[40]. 
  Diabetes is associated with an elevation of plasma FFAs 
which blunts insulin-mediated vasodilation and NO produc-
tion in humans, and insulin- or mixed meal-induced muscle 
microvascular recruitment in rats and humans [15,23,41,42]. 
It appears that FFAs contribute to microvascular insulin resis-
tance via the NF-κB pathway as pre-treatment with salsalate, 
an anti-inflammatory agent that inhibits NF-κB, markedly 
improves insulin’s microvascular action in muscle during sys-
temic lipid infusion [16]. This observation is consistent with in 
vitro experiments using cultured endothelial cells demonstrat-
ing that palmitate inhibits insulin-mediated phosphorylation 
of eNOS and NO production via increasing IKKβ activity [36,
43]. 
  Diabetes up-regulates the activity of RAS in the cardiovas-
cular system [44-46]. Angiotensin II, a terminal product of 
RAS, acts on the AT1R which cross-talks with the insulin sig-
naling cascades to cause insulin resistance, including an an-
tagonistic effect on insulin-mediated vasodilation, likely via 
AT1R-mediated NAD(P)H oxidase activation and increased 
production of superoxide and reduced NO bioavailability [44, 
47-50]. The AT1R mediates the vast majority of the cardiovas-
cular, renal, and adrenal actions of angiotensin II, resulting in 
arterial vasoconstriction, aldosterone secretion, and renal so-
dium reabsorption. We have recently reported that the AT1R 
also exerts potent tonic effect on muscle microvasculature. 
Systemic administration of AT1R blocker losartan acutely re-
cruits muscle microvasculature and increases muscle glucose 
extraction, suggesting a tonic restriction of the AT1R activity 
on muscle microvascular perfusion and substrate delivery [31]. 
On the other hand, selective activation of the AT1R (in the 
presence of specific AT2R blockade) by endogenous angioten-
sin II drastically reduces muscle microvascular perfusion and 
insulin delivery, resulting in reduced insulin-stimulated mus-
cle glucose disposal [14,31]. Whether this effect contributes to 87
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decreased cardiovascular morbidity and mortality and new 
onset of diabetes in patients on chronic treatment of AT1R 
blockers remain to be examined. Treatment of insulin resistant 
Zucker diabetic fatty rats for 15 weeks with an angiotensin-
converting enzyme (ACE) inhibitor quinapril did restore insu-
lin’s microvascular action [34]. 
CONCLUSION
Muscle microvasculature plays a pivotal role in the regulation 
of nutrient metabolism by providing the necessary exchange 
surface area between the plasma compartment and muscle in-
terstitium (Fig. 1). Insulin causes vasodilation in the insulin 
sensitive state to recruit muscle microvasculature. Several oth-
er factors, including exercise, mixed meal, GLP-1, and AT1R 
blockers, also recruit muscle microvasculature which may con-
tribute to increased insulin delivery to and action in muscle. 
Microvascular insulin resistance and dysfunction are closely 
related with metabolic insulin resistance in diabetes. Major 
factors that have been shown to cause metabolic insulin resis-
tance, including inflammatory cytokines, FFAs, and AT1R ac-
tivation, have all been shown to cause microvascular insulin 
resistance. Thus, muscle microvasculature could be a thera-
peutic target for diabetes prevention and control.
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